Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus

• Status: Completed
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Glucosamine (GlcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of chitosan with recently reported immunoregulatory capacity and anti-inflammatory effect and was administrated orally in osteoarthritis and atopic dermatitis therapy. Given the Oral lichen planus (OLP) T-cell-mediated pathogenesis; this drug seems to be a promising therapeutic option. The investigators compared clinical effectiveness of Glucosamine combined with two topical corticosteroid regimens to that of topical corticosteroid alone in symptomatic OLP and investigated therapeutic mechanism by examining treatment effect on expression of inhibitor kappa kinase alpha (IKKα) and interleukin-8 (IL-8) in OLP lesions.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Triamcinolone; Triamcinolone Acetonide; Triamcinolone diacetate; Triamcinolone hexacetonide

Criteria

Inclusion Criteria:

• Clinically and Histologically proven painful Bullous/erosive or atrophic forms of OLP

Exclusion Criteria:

• lichenoid lesions

• Presence of systemic conditions

• Smoking

• Known hypersensitivity or severe adverse effects to the treatment drugs or to any ingredient of their preparation

• Pregnancy or breast-feeding

• History of previous treatments potentially effective on OLP in last 3 months

• Loss of pliability or flexibility in the tissues involved by the oral lesions of lichen planus